Tobi Podhaler (Tobramycin) Patent Expiration, LOE Window & CMS Spending

Tobi Podhaler (Tobramycin) by Viatris: FDA Orange Book LOE 2030-11-04, 0 AB generics, $21.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorViatris
FDA Application & PathwayN201688 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2030-11-04
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$21.6M
2024 Medicare Part D Spend$11.6M
2024 Medicaid Spend$9.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.